David C. Hastings
Known title: DirectorCIK: 0001237401
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
ABUS Featured in Whale Alert List of 10 Health Care Stocks. Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.
Transaction History
| SCYX | ▲ Buy | Grant | 2,875 | $0 | 6/26/2026 | View on chart |
| SCYX | ▲ Buy | Grant | 23,000 | $0 | 6/26/2025 | View on chart |
| ABUS | ▲ Buy | Grant | 90,100 | $0 | 2/14/2025 | View on chart |
| ABUS | ▼ Sell | Open Market | 22,183 | $73K | 2/4/2025 | View on chart |
| SCYX | ▲ Buy | Grant | 23,000 | $0 | 6/20/2024 | View on chart |
| ABUS | ▼ Sell | Open Market | 9,593 | $22K | 2/2/2024 | View on chart |
| ABUS | ▲ Buy | Grant | 112,500 | $0 | 2/1/2024 | View on chart |
| SCYX | ▲ Buy | Grant | 10,000 | $0 | 6/15/2023 | View on chart |
| ABUS | ▲ Buy | Grant | 79,000 | $0 | 2/1/2023 | View on chart |
| SCYX | ▲ Buy | Grant | 10,000 | $0 | 6/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SCYNEXIS Wins $214M BARDA Contract for SCY-247
SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.
SCYNEXIS Wins $214M BARDA Contract for SCY-247. SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.